NSE: APOLLOHOSP · 29 September 2026 · Dated market coverage
- The stock is -2.27% at ₹8,659.00.
- Likely reason:Profit-taking and sector divergence amid elevated volume
- Approximate traded value is₹520.18 crore.
- It is -4.54% from its 52-week high and +29.31% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is Apollo Hospitals Enter. L Share Price Falling Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 600,737; 5-Day Avg. Volume: 455,898; 20-Day Avg. Volume: 304,762; Volume vs 20-Day Avg.: 1.97x; Delivery Quantity: 403,816; Delivery %: 66.29%; Number of Trades: 61,576.
Apollo Hospitals Enterprise Limited (APOLLOHOSP) declined during today’s trading session, settling at ₹8,659.0 after registering a loss of 2.27% compared to its previous close of ₹8,860.0. The stock opened slightly higher at ₹8,885.0 and touched a day’s high of ₹8,904.5 before facing sustained selling pressure that dragged it down to hit the session low of ₹8,659.0 at the close. Trading activity saw a notable pickup, with volume running significantly higher than usual—reaching 1.32 times the 5-day average and 1.97 times the 20-day average, indicating heightened participation as prices trended downward.
The broader market sentiment presented a mixed picture, with the benchmark Nifty slipping 0.28%, while the sectoral index, Nifty Pharma, managed to buck the trend and post a modest gain of 0.64%. Apollo Hospitals underperformed both the broader market and its own sector benchmark, retreating 2.0% over the past five days and 1.1% over a 20-day window, reflecting ongoing near-term consolidation despite a relatively supportive sector background.
While no major corporate catalyst or exchange announcement was published on the day of this price move to directly trigger the decline, the stock’s recent performance reflects profit-taking and technical weakness following a stretch of range-bound movement near its 52-week highs. Market participants continue to monitor underlying volume trends and delivery participation—which stood at 66.29%—alongside broader healthcare sector developments as the stock digests its prior gains.
low confidence
- Stock down 2.27% while Nifty Pharma sector gained 0.64%
- Volume was significantly elevated at 1.97x the 20-day average
- No fresh corporate announcements or fundamental news releases on the trading day
Ownership & Transaction Activity
Recent NSE pledge/encumbrance disclosures: SUNEETA REDDY: Pledge Revoke — 150000 shares (17-Nov-2025); PCR INVESTMENTS LIMITED: Pledge Revoke — 2300000 shares (16-Oct-2025); K VISHWESHWAR REDDY: Pledge — 70000 shares (29-Sep-2025)
Source: NSE PIT disclosure
WittyTrades Data Insight
Price Position:The stock is near the lower end of the day’s trading range.
Move From Open:-2.54%.
Intraday Range:2.77% of the previous close.
5-Day Performance:-2.00%; 20-Day Performance:-1.10%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Sustained delivery percentage (currently at 66.29%) to gauge institutional accumulation versus speculative short-term selling.
- Price action around immediate support zones following today’s test of the day’s low at ₹8,659.0.
- Performance relative to the Nifty Pharma sector benchmark to see if underperformance persists.
Catalyst note:No single confirmed news catalyst was reported on the trading day, indicating the price movement was driven by technical selling and volume-backed profit-taking.
Frequently Asked Questions
What is the likely reason for today’s move?
The decline appears to be driven by stock-specific profit-taking and technical selling following recent consolidation, as the stock fell 2.27% despite the Nifty Pharma sector gaining 0.64%. Trading volumes spiked above average (nearly 2x the 20-day norm), suggesting active liquidation without any single confirmed same-day news catalyst.
Is trading volume elevated?
Today’s volume is 600,737. The latest 20-day average available is 304,762, equivalent to about 1.97x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk